DS
RPRX

DRW Securities’s Repros Therapeutics Inc. RPRX Stock Holding History

DRW Securities’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-15,400
Closed -$413K – 296
2013
Q3 		$413K Buy
+15,400
New +$330K 0.03% 100

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

DRW Securities's RPRX Position: Q1 2014 in Review

DRW Securities sold out of Repros Therapeutics Inc. (RPRX) in Q1 2014, closing a stake of 14,000 shares — an estimated $256K sold.

DRW Securities first reported a position in RPRX in Q4 2013 and held it in 1 quarter. The position peaked at $256K in Q4 2013. 80 funds tracked by Wall St. Rank hold RPRX as of Q1 2014.

  • DRW Securities reported no remaining Repros Therapeutics Inc. position as of Q1 2014 after selling out during the quarter.
  • DRW Securities sold 14,000 Repros Therapeutics Inc. shares in Q1 2014, an estimated $256K.
  • DRW Securities first reported a position in Repros Therapeutics Inc. in Q4 2013 and held it in 1 quarter.
  • DRW Securities's Repros Therapeutics Inc. position peaked at $256K in Q4 2013.
  • 80 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2014.

Based on DRW Securities's 13F filing for Q1 2014, filed 16 May 2014.